| 000 | 04023nlm1a2200505 4500 | ||
|---|---|---|---|
| 001 | 662557 | ||
| 005 | 20231030041825.0 | ||
| 035 | _a(RuTPU)RU\TPU\network\33712 | ||
| 035 | _aRU\TPU\network\5872 | ||
| 090 | _a662557 | ||
| 100 | _a20200902a2020 k y0engy50 ba | ||
| 101 | 0 | _aeng | |
| 135 | _adrcn ---uucaa | ||
| 181 | 0 | _ai | |
| 182 | 0 | _ab | |
| 200 | 1 |
_aInfluence of Residualizing Properties of the Radiolabel on Radionuclide Molecular Imaging of HER3 Using Affibody Molecules _fM. V. Bukkel, S. S. Rinne, Xu Tianqi [et al.] |
|
| 203 |
_aText _celectronic |
||
| 320 | _a[References: 60 tit.] | ||
| 330 | _aHuman epidermal growth factor receptor type 3 (HER3) is an emerging therapeutic target in several malignancies. To select potential responders to HER3-targeted therapy, radionuclide molecular imaging of HER3 expression using affibody molecules could be performed. Due to physiological expression of HER3 in normal organs, high imaging contrast remains challenging. Due to slow internalization of affibody molecules by cancer cells, we hypothesized that labeling (HE)3-ZHER3:08698-DOTAGA affibody molecule with non-residualizing [125I]-N-succinimidyl-4-iodobenzoate (PIB) label would improve the tumor-to-normal organs ratios compared to previously reported residualizing radiometal labels. The [125I]I-PIB-(HE)3-ZHER3:08698-DOTAGA was compared side-by-side with [111In]In-(HE)3-ZHER3:08698-DOTAGA. Both conjugates demonstrated specific high-affinity binding to HER3-expressing BxPC-3 and DU145 cancer cells. Biodistribution in mice bearing BxPC-3 xenografts at 4 and 24?h pi showed faster clearance of the [125I]I-PIB label compared to the indium-111 label from most tissues, except blood. This resulted in higher tumor-to-organ ratios in HER3-expressing organs for [125I]I-PIB-(HE)3-ZHER3:08698-DOTAGA at 4 h, providing the tumor-to-liver ratio of 2.4 ± 0.3. The tumor uptake of both conjugates was specific, however, it was lower for the [125I]I-PIB label. In conclusion, the use of non-residualizing [125I]I-PIB label for HER3-targeting affibody molecule provided higher tumor-to-liver ratio than the indium-111 label, however, further improvement in tumor uptake and retention is needed. | ||
| 461 | _tInternational Journal of Molecular Sciences | ||
| 463 |
_tVol. 21, iss. 4 _v[1312, 16 p. ] _d2020 |
||
| 610 | 1 | _aтруды учёных ТПУ | |
| 610 | 1 | _aэлектронный ресурс | |
| 610 | 1 | _aHER3 | |
| 610 | 1 | _aaffibody | |
| 610 | 1 | _aradionuclide | |
| 610 | 1 | _amolecular imaging | |
| 610 | 1 | _aiodine | |
| 610 | 1 | _aPIB | |
| 610 | 1 | _aрадионуклиды | |
| 610 | 1 | _aвизуализация | |
| 610 | 1 | _aиод | |
| 701 | 1 |
_aBukkel _bM. V. |
|
| 701 | 1 |
_aRinne _bS. S. _gSara |
|
| 701 | 0 | _aXu Tianqi | |
| 701 | 1 |
_aLeitao _bCh. D. _gCharles Dahlsson |
|
| 701 | 1 |
_aStahl _bS. _gStefan |
|
| 701 | 1 |
_aLofblom _bJ. _gJohn |
|
| 701 | 1 |
_aOrlova _bA. M. _cspecialist in the field of medical technology _cSenior Researcher, Oncoteranostika Research Center, Ph.D _f1960- _gAnna Markovna _2stltpush _3(RuTPU)RU\TPU\pers\46554 |
|
| 701 | 1 |
_aTolmachev _bV. M. _cspecialist in the field of medical technology _cDirector of the Research Center "Oncoteranostika", Tomsk Polytechnic University, Ph.D _f1961- _gVladimir Maksimilianovich _2stltpush _3(RuTPU)RU\TPU\pers\46552 |
|
| 701 | 1 |
_aVorobjeva (Vorobyeva) _bA. G. _cspecialist in the field of medical technology _cSenior Researcher, Oncoteranostika Research Center, Ph.D _f1990- _gAnzhelika Grigorjevna _2stltpush _3(RuTPU)RU\TPU\pers\46556 |
|
| 712 | 0 | 2 |
_aНациональный исследовательский Томский политехнический университет _bИсследовательская школа химических и биомедицинских технологий _bНаучно-исследовательский центр "Онкотераностика" _h8442 _2stltpush _3(RuTPU)RU\TPU\col\27561 |
| 801 | 2 |
_aRU _b63413507 _c20200902 _gRCR |
|
| 856 | 4 | _uhttps://doi.org/10.3390/ijms21041312 | |
| 942 | _cCF | ||